Patients with bladder cancer commonly present with post-renal acute kidney injury (AKI). Here we describe a rare case of AKI, developed within 15 months of the anti-programmed death-ligand 1 antibody therapy in a patient with bladder cancer and normally functioning suprapubic urinary catheter.
van der HeijdenMSLoriotYDuránI, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma: a long-term overall survival and safety update from the phase 3 IMvigor211 clinical trial. Eur Urol2021; 80(1): 7–11.
2.
XipellMVictoriaIHoffmannV, et al. Acute tubulointerstitial nephritis associated with atezolizumab, an anti-programmed death-ligand 1 (PD-L1) antibody therapy. Oncoimmunology2018; 7(7): e1445952.
3.
MamloukOSelametUMachadoS, et al. Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience. J Immunother Cancer2019; 7(2): 1–13.
4.
YılmazAMiriliCBiliciM, et al. Possible atezolizumab-associated acute kidney injury and immune thrombocytopenia. J Oncol Pharm Pract2020; 26(7): 1791–1794.
5.
SeethapathyYZhaoSStrohbehnIA.Incidence and clinical features of immune-related acute kidney injury in patients receiving programmed cell death Ligand-1 inhibitors. Kidney Int Rep2020; 5: 1700–1705.
